Research News and Research

RSS

Hopkins stem cell research to examine how gene variants cause blood clotting disorders

Johns Hopkins scientists have launched a pioneering research program to create, for the first time, human platelet cells from stem cells in order to study inherited blood clotting abnormalities ranging from clots that cause heart attacks and stroke to bleeding disorders.

4 Aug 2011

Vampire bats can smell blood-rich prey: Study

In the labs of University of California, San Francisco and from the wilds of Venezuela scientists have discovered how vampire bats have evolved over the years with a unique weapon that enables them to zero in for a ravenous feed on the warmest blood vessels of their prey.

4 Aug 2011

Older men, women have different opinions on body function and appearance

When it comes to satisfaction with body function and body appearance, older men and women have different opinions, although physical activity does improve satisfaction in both sexes, according to new study by a Baylor University researcher.

4 Aug 2011

Bad teeth in Ozzie kids worries dental health experts

According dental health experts, changes in diet, un-flouridated bottled water and the habit of “constantly bathing” ones teeth in sugary drinks is to blame for the rising number of decaying and rotten teeth found in children

4 Aug 2011

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2011.

4 Aug 2011

Siemens receives Health Canada Medical Device License for Biograph mMR

Siemens Canada Healthcare has received a Health Canada Medical Device License for the Biograph mMR.

4 Aug 2011

Centenarians have good genes rather than good lifestyles: Study

The team of researchers interviewed 477 people who were living independently and were 95 and older who were participating in a longevity research project that is trying to understand why centenarians live as long as they do.

4 Aug 2011

Instituto Bioclon receives FDA approval for Anascorp to treat Centruroides scorpion sting

The U.S. Food and Drug Administration today approved Anascorp, the first specific treatment for a scorpion sting by Centruroides scorpions in the United States.

4 Aug 2011

Viewpoints: Geithner, Bowles, Simpson, Ryan, Vladeck, Wilensky on health spending and the deficit

The agreement sets up a powerful mechanism for agreement on tax reforms to strengthen growth, and entitlement reforms to strengthen programs such as Medicare. A congressional committee with fast-track authority will have a Nov. 23 deadline to recommend a balanced package of long-term reforms to produce $1.5 trillion in additional deficit reduction.

4 Aug 2011

Par Pharmaceutical reports second quarter total revenues of $224.2 million

Par Pharmaceutical Companies, Inc. today reported results for the second quarter ended June 30, 2011.

3 Aug 2011

Acceleron, Celgene enter development collaboration for ACE-536 protein therapeutic to treat anemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, and Celgene Corporation today announced that the companies have entered into a joint development and commercialization agreement for ACE-536 for the treatment of anemia.

3 Aug 2011

SuperGen second quarter net income decreases to $903,000

SuperGen, Inc. today reported financial results for the second quarter ended June 30, 2011. The Company reported net income for the 2011 second quarter of $903,000, or $0.01 per basic and diluted share, compared with $961,000, or $0.02 per basic and diluted share, for the same prior year period.

3 Aug 2011

Celldex second quarter net loss increases to $10.2 million

Celldex Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2011. Celldex reported a net loss of $10.2 million, or $0.27 per share, for the second quarter of 2011 compared to a net loss of $9.5 million, or $0.30 per share, for the second quarter of 2010.

3 Aug 2011

Illumina and University of Oxford collaborate to sequence whole genomes

Illumina, Inc. today announced it will collaborate with the University of Oxford to sequence the whole genomes of 500 individuals afflicted with a range of life-threatening diseases that pose major challenges in diagnosis, treatment, and care. Illumina HiSeq™ 2000 systems will be used to generate sequence data for the 500 genomes.

From Illumina, Inc. 3 Aug 2011

First Edition: August 3, 2011

Today's headlines showcase continuing reports about the impact the debt deal might have on health care providers, as well as how the agreement's "super committee" will be charged with finding spending reductions in Medicare, Medicaid and a range of other government programs.

3 Aug 2011

Zalicus second quarter revenue decreases to $1.8 million

Zalicus Inc. today reported financial results for the second quarter ended June 30, 2011.

3 Aug 2011

Researchers discover biological mechanism behind sarcopenia

Researchers at Columbia University Medical Center have discovered the biological mechanism behind age-related loss of muscle strength and identified a drug that may help reverse this process.

3 Aug 2011

New approach reduces cyanogen, enhances nutritional value in root crop

Researchers working at The Donald Danforth Plant Science Center have made an another advancement in their efforts to improve the root crop cassava which is a major source of calories to 700 million people worldwide, primarily living in the developing world.

3 Aug 2011

Marital instability impacts child's sleep patterns

When parents fight, infants are likely to lose sleep, researchers report. "We know that marital problems have an impact on child functioning, and we know that sleep is a big problem for parents," said Jenae M. Neiderhiser, professor of psychology, Penn State.

3 Aug 2011

BioClinica second quarter service revenues increase 8.7% to $16.9 million

BioClinica Inc., a global provider of clinical trial management solutions, today announced its financial results for the second quarter and six months ended June 30, 2011.

From Clario 3 Aug 2011